<DOC>
	<DOCNO>NCT02115997</DOCNO>
	<brief_summary>This perspective , Phase IV , multi-center , single arm , open-label , interventional study adult participant Wegener 's granulomatosis ( granulomatosis polyangiitis [ GPA ] ) microscopic polyangiitis . Participants treat rituximab ( Ristova ) glucocorticoid . Rituximab administer intravenous ( IV ) infusion dose 375 milligram per meter square ( mg/m^2 ) body surface area weekly Weeks 1 4 . Participants also receive one three pulse methylprednisolone ( 1000 milligram [ mg ] ) , follow taper dose oral prednisolone ( start dose 1 mg per kilogram per day ) . The dose oral prednisone reduce per evaluation investigator till participant completely drug . The participant follow duration 6 month date start rituximab therapy three follow-up visit Days 52 , 112 172 . All adverse event occur period capture .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy Rituximab Combination With Glucocorticoids Participants With Wegener 's Granulomatosis Microscopic Polyangitis</brief_title>
	<detailed_description />
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Male nonpregnant , nonnursing female Diagnosed Wegener 's granulomatosis Microscopic polyangiitis accord definition Chapel Hill Consensus Conference Participants either newly diagnose relapse disease Participants must active disease per BVAS/WG great equal ( &gt; /= ) 3 would normally require treatment cyclophosphamide ( CYC ) Participants willing practice medically acceptable contraception 1 year completion rituximab therapy Participants must severe disease i.e . one major BVAS/WG item depict severity disease severe enough require treatment CYC . Participants must positive either proteinase 3antineutrophil cytoplasmic antibody ( PR3ANCA ) myeloperoxidaseantineutrophil cytoplasmic antibody ( MPOANCA ) screen History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Participants severely immunocompromised state Participants severe heart failure ( New York Heart Association Class IV ) severe , uncontrolled cardiac disease Participants active severe infection history recurrent bacterial , viral , fungal , mycobacterial infection Participants live vaccine few 4 week first dose rituximab Any condition put participant undue risk rituximab therapy per local prescribe information Investigator 's judgment Participants previous treatment rituximab Participants previous treatment alemtuzumab Participants treatment infliximab within previous 3 month Participants treatment adalimumab within previous 2 month Participants treatment etanercept within previous month Participants investigational medication within previous month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>